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ABSTRACT (word count = 250/250) 
Background: Prostate cancer is a leading incident cancer worldwide and modifiable lifestyle 
factors for prostate cancer risk reduction remain largely unknown. Polyunsaturated fatty acids 
(PUFAs), in particular ω-3 PUFAs have been suggested to be anti-inflammatory, whereas ω-6 
PUFAs have been shown to be inflammatory. In our study, we utilized genetic variants 
associated with plasma PUFA levels to examine the association between PUFAs and prostate 
cancer risk using Mendelian randomization. 
Methods: We utilized individual-level data from a large consortium of 22,721 cases and 23,034 
controls with available genetic variants that were either genotyped or imputed and related to 
blood PUFA levels. Polygenic risk scores (PRS), both unweighted and externally-weighted, were 
constructed for each PUFA and used to evaluate the relation between PRS with prostate cancer 
risk using unconditional logistic regression models adjusted for age and principal components for 
European ancestry. In addition to the individual-level analysis, we compared our results to an 
estimate using two-sample method utilizing GWAS summary statistics. 
Results: The genetic instrument for arachidonic acid was the strongest with approximately 33% 
variation explained.  The age- and principal components-adjusted association for weighted PRS 
for arachidonic acid was null (OR=1.01; 95%CI=0.99, 1.02), which was nearly identical to the 
association estimated from the two-sample method. Similarly, no associations were observed for 
the other PUFAs.  
Conclusions: No association was observed for PUFAs in relation to prostate cancer risk. Future 
studies should consider utilizing additional genetic variants to further strengthen the genetic 
instrument for those PUFAs for which the percent variation explained was low. 
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INTRODUCTION 
 Prostate cancer is one of the leading incident cancers among Caucasian men worldwide 1. 
The increased incidence could be attributed to screening leading to over diagnosis of prostate 
cancer 2. Over diagnosis may result in over treatment and resulting in long-term side-effects, thus 
providing the impetus for new treatment and screening recommendations 3. Identifying 
modifiable prostate cancer risk reduction strategies could also help to alleviate the burden of 
prostate cancer in addition to improved screening and treatment guidelines.  Furthermore, men 
presenting with higher stage at diagnosis tend to have poor survival, further motivating the 
search for modifiable prostate cancer risk factors. Specifically, the identification of easily 
modifiable dietary factors, for prostate cancer remain inconclusive. 
 Several epidemiologic studies have previously examined the relation between 
polyunsaturated fatty acids (PUFAs) and prostate cancer risk 4–7. Given the role that PUFAs play 
in prostate carcinogenesis, with suggested anti-inflammatory effects for ω-3 PUFAs and 
inflammatory effects for ω-6 PUFAs 8, examination of these nutritional factors in hopes of 
identifying potential risk reduction strategies is alluring. A recent meta-analysis summarizing 
prospective studies of long-chain ω-3 PUFA intake and prostate cancer incidence reported null 
results for self-reported dietary intake and biomarker measures of PUFAs 4. However, 
observational studies of dietary factors and cancer risk could suffer from biases, including 
confounding, selection bias, and reverse causation. Reverse causation in studies of prostate 
cancer and diet may be of particular concern given those individuals with benign prostate cancer 
may not be treated for several years under the current treatment guidelines. Additionally, 
measurement error is an important consideration in studies examining dietary exposures given 
several different assessment methods exist for measuring diet; including food frequency 
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questionnaires and biomarker measurements of fatty acids. Each measurement strategy presents 
advantages and disadvantages, including recall bias, and exposure misclassification due to 
irrelevant etiologic exposure window. Given these potential limitations of observational studies, 
exploring novel methods for identifying prostate cancer risk factors are needed. 
 Mendelian randomization is based on the principle of random assortment of alleles at 
conception, and may be able to identify causal risk factors for disease. The method utilizes 
genetic variants as a proxy for an exposure, also known as genetic instrument. . Previous 
genome-wide association studies (GWAS) have identified several variants that are related to 
plasma PUFAs and explain a significant proportion of variation in PUFA levels, thus making 
PUFAs an appealing candidate for a Mendelian randomization analysis. 
In this manuscript, we sought to identify the potentially causal association between 
PUFAs and risk of developing prostate cancer utilizing data from a large consortium and several 
GWAS-reported PUFA genetic variants using both individual-level data and the two-sample 
method using published summary statistics.  
 
METHODS 
Study population 
We utilized the resources from the Prostate Cancer Association Group to Investigate 
Cancer Associated Alterations in the Genome (PRACTICAL), a large consortium of prostate 
cancer genetic association studies. The goal of the consortium is to elucidate the role of genetics 
in prostate cancer etiology. In our analysis, we excluded those individuals who were not of 
European ancestry (n=1,189) and all individuals from the Washington University Genetics Study 
(WUGS) case-only study (n=944), and the Prostate Cancer Mechanisms of Progression and 
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Treatment (PrOMPT) study which had only 2 controls (n=168). The final analytic dataset 
consisted of 45,755 individuals (22,721 cases and 23,034 controls). 
 
iCOGS array 
The PRACTICAL study population was genotyped using a custom Illumina Infinium 
array (iCOGS) as part of the Collaborative Oncological Gene-environment Study (COGS), 
including more than 85,000 prostate cancer-related SNPs selected from four previous GWAS 
(i.e., UKGPCS, CGEMS, BPC3, and CAPS), fine mapping of known prostate cancer 
susceptibility regions at the time of custom chip design, and from candidate gene studies 
examining important biologic pathways (including hormone metabolism, cell cycle, and DNA 
repair) 9. Standard quality control protocol were followed by excluding individuals with 
genotyping call rates <95%, heterozygosity greater than or less than 4.89 standard deviations 
from the ethnicity-specific mean, and excluded duplicates and relative pairs 9,10. SNPs with call 
rates <95% were excluded, as well as those deviating from Hardy-Weinberg Equilibrium among 
the controls at p value <1x10-7 9,10. Among the nine SNPs included in our analysis, three were 
directly genotyped (i.e., rs780094, rs2236212, and rs174538) and six were imputed (i.e., 
rs3734398, rs3798713, rs1074011, rs174547, rs2727270, and rs1696695) with high quality (r2 > 
0.76).  SNPs were imputed in two stages; first using SHAPEIT (http://www/shapeit.fr/) by 
chromosome and chunk and then phased with the haplotypes from 1000 Genomes Phase 3 
(March 2012 release) 9,10.  
 
Instrumental variables 
We utilized results from previously published genome-wide association studies 
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conducted among the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) consortium examining plasma levels of ω-6 11 and ω-3 12 PUFAs in order to identify 
genetic variants associated with plasma PUFAs. We also considered several variants identified 
from metabolomics literature; however, many of the SNPs identified were the same or in high 
linkage disequilibrium with those identified from the two CHARGE GWAS. Therefore, we 
identified SNPs (n=23) associated with any PUFA from these two previously conducted GWAS. 
Among these, 14 were associated with the essential PUFAs [i.e., linoleic acid (LA), arachidonic 
acid (AA), alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid 
(DPA), and docosahexaenoic acid (DHA)]. Finally, 9 of these SNPs were independent (r2 < 0.1), 
and thus were utilized in the instrumental variable for the Mendelian randomization analyses. 
Please refer to Supplemental Figure 1 for summary of SNP selection.  
For each variant selected the allele that increased levels of plasma PUFA levels was 
considered the effect allele. The following variant(s) were selected as the instrument for each 
PUFA: (1) LA: rs10740118, rs174547, rs2727270, and rs16966952; (2) AA: rs174547 and 
rs16966952; (3) ALA: rs174547; (4) EPA: rs3798713 and rs174538; (5) DPA: rs780094, 
rs3734398, and rs174547; (6) DHA: rs2236212. A couple of these selected variants (i.e., 
rs174547 and rs16966952) were associated with multiple PUFAs, and thus were not exclusive to 
any particular genetic instrument. Table 1 lists the SNPs utilized in the genetic instrument and 
their summary estimates for the effect allele obtained from previously published PUFA GWAS 
11,12. Also included in this table is the proportion of variance explained per allele and genetic 
instrument. 
 
Polygenic risk score (PRS) 
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For analyses using individual-level data, a polygenic risk score (PRS) was constructed for 
each PUFA separately, and consisted of the SNPs associated with each fatty acid. A PRS was 
constructed for every individual by taking the sum of the effect alleles for the SNPs included in 
each genetic instrument. Allele dosage was utilized for those SNPs that were imputed. We 
additionally created a weighted PRS (wPRS) where effect alleles were weighted according to 
their estimates from previously published PUFA GWAS 11,12, thus giving higher weight to those 
alleles with stronger associations with PUFA levels and reflecting an increase in PUFA levels 
measured as percentage of total plasma fatty acids. The beta estimates for each SNP are listed in 
Table 1. The range for each PRS and wPRS was PUFA-specific given the number of SNPs 
utilized for each PUFA genetic instrument was different. Summary statistics and theoretical 
range for the PRS and wPRS according to each PUFA subtype are provided in Supplemental 
Table 1. 
 
Statistical analysis 
 Unconditional logistic regression was used to estimate the association between 
genetically predicted PUFAs and risk of prostate cancer per one standard deviation increase in 
either the PRS or wPRS.  All models were adjusted for age and eight principal components for 
European ancestry. We further assessed the relation between wPRS and prostate cancer risk 
using restricted cubic splines for those genetic risk scores including more than one variant (i.e., 
LA, AA, EPA, DPA). Supplemental Figures 2-5 display the shape of the dose-response between 
the wPRS and log-odds of prostate cancer from the restricted cubic spline models. Restricted 
cubic spline plots were generated using the SAS macro developed by Desquilbet and Mariotti 13. 
Several stratified analyses were conducted to explore the relation between PUFAs and prostate 
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cancer risk among subgroups, including smoking status (ever vs. never), median age at diagnosis 
(<62 vs. ≥62 years), disease status (advanced vs. non-advanced), and method of prostate cancer 
detection (screen vs. clinically detected). Likelihood ratio tests were conducted comparing nested 
models for the multiplicative interaction term in order to assess statistically significant 
heterogeneity across strata. Analyses were conducted using SAS version 9.4 (Cary, North 
Carolina).  
 
Analyses using summary statistics (two-sample method) 
 Summary statistics from the previous PUFA GWAS 11,12 were used in tandem with the 
summary estimates from PRACTICAL consortium to calculate the Mendelian randomization 
estimate using an inverse-variance weighted meta-analysis approach  14. The Mendelian 
randomization estimate (β̂
IVW
) and standard error [se(β̂
IVW
)] was calculated as follows: 
β̂
IVW
= 
∑ XgYgσYg
-2g
i=1
∑ Xg
2g
i=1
σYg
-2
 , se(β̂
IVW
)=√
1
∑ Xg
2σYg
-2g
i=1
 
, where the Xg summary estimate for each SNP (g) included in the genetic instrument with levels 
of PUFA (X) obtained from the previously published GWAS 11,12. The Yg and σYg estimates 
were obtained from the PRACTICAL consortium for each SNP in relation to prostate cancer risk 
(Y). Odds ratios and 95% CI were calculated using β̂
IVW
 and se(β̂
IVW
). We further standardized 
the Mendelian randomization ORs and 95% CIs to represent an increase in prostate cancer risk 
per one standard deviation increase in the wPRS, thus representing a standard deviation increase 
in percentage of PUFA levels per total plasma fatty acids. 
 
Assessing pleiotropy 
 Given several SNPs were included in different PUFA genetic instruments, we conducted 
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a sensitivity analysis to take this pleiotropy into consideration, thus further evaluating the 
strength of the genetic instruments used in this analysis. Using a weighted-regression based 
approach the estimates for the association between the SNP and outcome (Yg) were regressed on 
the association between the SNP and the main PUFA exposure (Xg) weighted by the inverse-
variance (σYg-2), after adjusting for the association between the SNP and other PUFAs 15,16. 
Supplemental Table 6 presents the results from this sensitivity analysis with several different 
adjustment sets. 
 
RESULTS 
 In Table 1, we provide a list of SNPs and their GWAS-reported associations that were 
utilized in the construction of the weighted PRS. Each PUFA instrument explained anywhere 
from 0.65% (for DHA) to approximately 33% (for AA) of variation in exposure. Due to the large 
size of the PRACTICAL consortium, the F-statistic for all the genetic variants was large (all F-
statistics were >10) indicating a strong genetic instrument for the PUFA exposures of interest 17. 
 The associations between one standard deviation increase in PRS and wPRS in 
association with prostate cancer risk are presented in Table 2.  The associations presented for 
majority of PUFAs when modeled as either PRS or wPRS were null.  Supplemental Figures 2-4 
present the shape of the non-linear dose-response for the association between the wPRS (for LA, 
AA, EPA, and DPA) and the log-odds of prostate cancer from the restricted cubic spline model. 
Furthermore, associations between the wPRS and prostate cancer risk when modeled using the 
restricted cubic splines were also null (data not shown).  
 Also included in Table 2, are the results from the two-sample method using summary 
statistics scaled per one standard deviation unit increase in the wPRS. All associations with 
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between PUFAs and prostate cancer risk were null, similar to the results from the individual 
level data. 
  
DISCUSSION 
 In this analysis we examined the association between genetically predicted PUFAs (via 
construction of polygenic risk score) using individual-level data and summary statistics for 
PUFAs in relation to prostate cancer risk.  All results suggest a null association for the 
association between PUFAs and risk of developing prostate cancer. 
 Our results from both the individual-level analysis and the two-sample method are similar 
to previously published observational studies. Meta-analysis results from previous studies among 
Caucasian populations reported null association for studies examining self-reported dietary 
intake of long-chain ω-3 PUFAs (95% CI = 0.93, 1.09), and a modest increased risk for studies 
examining associations with biomarkers (summary RR = 1.07; 95% CI = 0.94, 1.20) 4. The meta-
analysis also indicate prostate cancer risk reductions for studies examining DPA intake for both 
measures via self-report (summary RR = 0.92; 95% CI = 0.71, 1.19) and biomarker (summary 
RR = 0.85, 95% CI = 0.72, 0.99). Similarly, results from another meta-analysis of prospective 
studies reported null associations with high intake of ALA in relation to prostate cancer risk 5.  
For ω-6 PUFAs, a systematic review reported no strong positive association for AA in relation to 
prostate cancer risk 7, nor was an association observed for a meta-analysis of LA and prostate 
cancer risk 6. 
 Although this study was sufficiently large to detect associations for the relation between 
PUFAs and prostate cancer incidence, several limitations still remain. First, Mendelian 
randomization assumes the genetic instrument is: (1) associated with the exposure; (2) not 
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associated with any confounders of the exposure-outcome association; and (3) independent of the 
outcome given the exposure and confounders (i.e., the genetic instrument only affects the 
outcome via the exposure of interest) 15,16 The validity of the Mendelian randomization estimate 
hinges on these assumptions. In our analysis, even though F-statistics for all the genetic 
instruments were large (>10) suggesting strong genetic instruments, this likely reflects the large 
sample size utilized in this analysis. Thus, perhaps a more important consideration of instrument 
strength for this analysis is the percent variation explained by each genetic instrument. In our 
analysis, the genetic instrument for AA explained the largest proportion of variation in plasma 
AA levels (~33%), and perhaps the null association reported for AA and prostate cancer risk in 
this analysis reflects the true non-association. Although this analysis used several common 
GWAS-identified variants in the PRS, there are likely additional rare variants with large effects 
that were not included in this analysis and have yet to be discovered. Thus, the PRS for PUFAs 
could be further improved once additional rare variants with potentially large effects are 
identified. Further replication from others is required to elucidate the true association for other 
PUFAs, including the long-chain ω-3 PUFAs for which anti-inflammatory action has been 
suggested in laboratory studies 8.   
This analysis also has several strengths. First, in our analysis we conducted both an 
individual level analysis (via construction of a PRS) and the two-sample method using summary 
statistics. In the individual-level analysis, we controlled for potential confounders for the 
association between the PRS and prostate cancer risk, including principal components for 
European ancestry. Also, the individual-level analysis allowed for the examination of subgroup 
effects by conducting stratified analyses. Additionally, we conducted our analysis among a large, 
consortium data from PRACTICAL. We did not observe any substantial pleiotropic effects when 
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we conducted the weighted-regression via the method proposed by Burgess, et al. 15,16. 
Nevertheless, we are unable to completely rule out the impact of unknown pleiotropic effects 
which could reduce the validity of the Mendelian randomization estimate.  Lastly, the proportion 
of variation explained by the SNPs included in the genetic instrument for AA was high, and thus 
the Mendelian randomization association may reflect the true null association, but requires 
confirmation by others, using instruments comprising additional variants and explaining a larger 
percentage of variation in fatty acid levels. 
In conclusion, we report null associations between PUFAs (both ω-3 and ω-6) in relation 
to prostate cancer incidence using data from a large consortium. Specifically, we report no 
association for AA in relation to prostate cancer incidence, for which the strength of the 
instrument and proportion of variation explained, was high. We conducted instrumental variable 
analyses using both individual-level data and summary statistics. Future investigations should 
explore the relation between other PUFAs (namely the long-chain ω-3 PUFAs) utilizing 
additional genetic variants (including rare variants with large effects) in order to further elucidate 
the association between PUFAs and prostate cancer. 
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Table 1.  Effect estimates for plasma phospholipid levels of polyunsaturated fatty acids (PUFAs, % of total fatty acids) for genome-
wide significant (p < 5x10-8), independent (r2 < 0.1) genetic variants reported from previous GWAS 11,12  
Chr SNP 
GRCh37/hg19 
Position 
Allelea EAF β SE p 
% VEb % VE F statistic 
per IVd per allele per IVc 
Linoleic acid (LA, 18:2n6)         
10 rs10740118 65101207 C/G 0.56 0.248 0.043 8.08E-09 0.2-0.7   
11 rs174547 61570783 T/C 0.32 1.474 0.042 4.98E-274 7.6-18.1   
11 rs2727270 61603237 T/C 0.44 0.690 0.070 2.60E-21 0.5-2.4   
16 rs16966952 15135943 A/G 0.31 0.351 0.044 1.23E-15 0.5-2.5 8.8-23.6e 1104-3533 
Arachidonic acid (AA, 20:4n6)         
11 rs174547 61570783 T/C 0.68 1.691 0.025 3.00E-971 32.63   
16 rs16966952 15135943 A/G 0.69 0.199 0.031 2.43E-10 0.44 33.07 11,302 
Alpha-linolenic acid (ALA, 18:3n3)         
11 rs174547 61570783 T/C 0.33 0.016 0.001 3.47E-64 1.03 1.03 476 
Eicosapentaenoic acid (EPA, 20:5n3)         
6 rs3798713 11008622 C/G 0.43 0.035 0.005 1.93E-12 0.36   
11 rs174538 61560081 A/G 0.72 0.083 0.005 5.37E-58 1.69 2.05 479 
Docosapentaenoic acid (DPA, 22:5n3)         
2 rs780094 27741237 T/C 0.41 0.017 0.003 9.04E-09 0.46   
6 rs3734398 10982973 T/C 0.43 0.040 0.003 9.61E-44 2.74   
11 rs174547 61570783 T/C 0.67 0.075 0.003 3.79E-154 8.38 11.58 1997 
Docosahexaenoic acid (DHA, 22:6n3)         
6 rs2236212 10995015 C/G 0.57 0.113 0.014 1.26E-15 0.65 0.65 299 
Note: 
a Allele associated with an increase in PUFA levels is in bold, and is considered the effect allele. 
b % variation explained (VE) = [2*β2*RAF*(1-RAF) / var(PUFA)]*100. 
c
 % VE per IV = sum of the %VE per allele for each SNP included in the IV. 
d F-statistic is a measure of the strength of the genetic instrument and is calculated as follows: [R2*(n-1-k)] / [(1-R2)*k], where R2 = % variation explained, n= 
sample size, k=total number of instrumental variables. 
e Ranges for % VE per SNP and % VE IV as reported in Guan, et al., 2014. 
SE = standard error, EAF = effect allele frequency, SNP = single nucleotide polymorphism, IV = instrumental variable 
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Table 2.  Associations for 1 SD unit increase in PUFAs and prostate cancer risk from analyses using individual-level data and two-
sample summary statistics 
PUFA 
 Individual-level data  
Two-sample 
summary statistics  PRS  
% of total fatty acids 
(wPRS) 
 
 ORa 95% CI p  ORa 95% CI p  ORb 95% CI p 
ω-6 PUFAs             
LA  1.00 0.99, 1.02 0.91  1.00 0.98, 1.01 0.67  1.00 0.98, 1.02 0.98 
AA  1.00 0.98, 1.03 0.69  1.01 0.99, 1.02 0.43  1.01 0.99, 1.02 0.55 
ω-3 PUFAs             
ALA  0.99 0.96, 1.02 0.41  0.99 0.97, 1.01 0.41  0.99 0.98, 1.01 0.53 
EPA  1.01 0.99, 1.03 0.30  1.01 0.99, 1.03 0.29  1.01 0.99, 1.03 0.44 
DPA  1.01 1.00, 1.03 0.07  1.01 0.99, 1.03 0.14  1.01 0.99, 1.03 0.32 
DHA  1.01 0.98, 1.03 0.62  1.00 0.99, 1.02 0.62  1.00 0.98, 1.02 0.96 
Note: 
a Adjusted for age and 8 principal components for European ancestry. 
b Mendelian randomization (MR) estimate derived using summary statistics 14 
 
 
 
